<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264705</url>
  </required_header>
  <id_info>
    <org_study_id>STU 062010-150</org_study_id>
    <nct_id>NCT01264705</nct_id>
  </id_info>
  <brief_title>Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer</brief_title>
  <official_title>A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of&#xD;
      bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC). This&#xD;
      study will be activated at the UT Southwestern Medical Center, comprised of The Harold C.&#xD;
      Simmons Comprehensive Cancer Center, UT Southwestern Hospitals-St. Paul and Parkland Memorial&#xD;
      Hospital System. Advanced HCC is defined as disease that is not amenable to surgical&#xD;
      resection or orthotopic liver transplantation or is metastatic in nature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are looking for men or women aged 18 years or older with hepatocellular&#xD;
      carcinoma not suitable for surgical resection or hepatic transplantation. Prior locoregional&#xD;
      therapy including but not limited to transarterial chemoembolization (TACE), radiofrequency&#xD;
      ablation (RFA) or ethanol injection is allowed as long as the treatment was 4 weeks previous.&#xD;
      Patients must be Child-Pugh A with no previous treatment with sorafenib or other vascular&#xD;
      endothelial growth factor (VEGF) inhibitors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up.</measure>
    <time_frame>Treatment initiation to first evidence of disease progression or last follow-up, an average of 24 months</time_frame>
    <description>Median radiographic time to progression (TTP) was calculated from treatment initiation to first evidence of disease progression or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-progression data was calculated using Greenwood's formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Dose Limiting Toxicity</measure>
    <time_frame>8 months.</time_frame>
    <description>Dose limiting toxicity by serious adverse events by CTCAE version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, as Measured by the Number of Patients With Adverse Event Related to the Treatment That Experienced Grade 3 or Greater.</measure>
    <time_frame>Up to 3 months of patient enrollment (phase 1)</time_frame>
    <description>Safety was measured by the number of patients with at least one adverse event as assess by NCI Common Terminology criteria for adverse events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Months of Overall Survival Calculated From Treatment Initiation to Death or Last Follow-up.</measure>
    <time_frame>Treatment initiation to death or last follow-up, an average 24 months</time_frame>
    <description>Median months of overall survival was calculated from treatment initiation to death or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for median months of overall survival was calculated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.</measure>
    <time_frame>Treatment initiation to first evidence of death from advanced liver cancer or last follow-up, an average of 12 months</time_frame>
    <description>Median months of disease specific survival was calculated from treatment initiation to first evidence of death from advanced liver cancer or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-disease specific survival data was calculated using Greenwood's formula.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab (0.3 mg/kg) and sorafenib</intervention_name>
    <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
    <arm_group_label>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab (1.0 mg/kg ) and sorafenib</intervention_name>
    <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
    <arm_group_label>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab (3.0 mg/kg) and sorafenib</intervention_name>
    <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
    <arm_group_label>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion&#xD;
             listed below:&#xD;
&#xD;
               -  Histologically confirmed.&#xD;
&#xD;
               -  MRI or CT consistent with liver cirrhosis and at least one solid liver lesion &gt;2&#xD;
                  cm with early enhancement and delayed enhancement washout regardless of AFP.&#xD;
&#xD;
               -  AFP &gt;400 ng/ml and evidence of at least one solid liver lesion &gt;2 cm regardless&#xD;
                  of specific imaging characteristics on CT or MRI.&#xD;
&#xD;
          2. Locally advanced or metastatic disease.&#xD;
&#xD;
          3. Patients with locally advanced disease must have disease deemed to be unresectable or&#xD;
             not eligible for hepatic transplantation. Determination will occur in the weekly GI&#xD;
             DMT meeting by surgical oncologists and transplant surgeons.&#xD;
&#xD;
          4. Measurable disease, as defined as lesions that can accurately be measured in at least&#xD;
             one dimension (longest diameter to be measured) according to Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST, version 1.1) at least 2 cm with conventional&#xD;
             techniques or at least 1 cm with spiral computed tomography.&#xD;
&#xD;
          5. Child-Pugh Score A.&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.&#xD;
&#xD;
          8. Absolute neutrophil count ≥ 1,500 cells/mm3.&#xD;
&#xD;
          9. Platelet count ≥ 75,000 cells/mm3.&#xD;
&#xD;
         10. Total bilirubin ≤ 3.0 mg/dl.&#xD;
&#xD;
         11. Hemoglobin ≥ 8.5 g/dl.&#xD;
&#xD;
         12. AST and ALT ≤ 5.0 times upper limit of normal.&#xD;
&#xD;
         13. D-dimer ≤ 3 times upper limit of normal.&#xD;
&#xD;
         14. INR ≤ 1.8 (therapeutic anticoagulation allowed as long as medically indicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          2. Symptomatic or clinically active brain metastases.&#xD;
&#xD;
          3. Major surgery within previous 4 weeks.&#xD;
&#xD;
          4. History of thromboembolic events (including both pulmonary embolisms and deep vein&#xD;
             thrombosis); central venous catheter-related thrombosis &gt; 6 months prior is allowed.&#xD;
&#xD;
          5. Prior adjuvant therapy with sorafenib or other Raf/MEK/RAS or VEGFR inhibitors. Prior&#xD;
             adjuvant therapy is allowed provided it was completed &gt; 6 months ago and there is&#xD;
             documented recurrence of hepatocellular carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam C Yopp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Adam Yopp</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>GI Cancer</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01264705/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bavituximab:0.3 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="P2">
          <title>Bavituximab: 1.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="P3">
          <title>Bavituximab: 3.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bavituximab:0.3 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="B2">
          <title>Bavituximab: 1.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="B3">
          <title>Bavituximab: 3.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
          <description>Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up.</title>
        <description>Median radiographic time to progression (TTP) was calculated from treatment initiation to first evidence of disease progression or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-progression data was calculated using Greenwood's formula.</description>
        <time_frame>Treatment initiation to first evidence of disease progression or last follow-up, an average of 24 months</time_frame>
        <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up.</title>
          <description>Median radiographic time to progression (TTP) was calculated from treatment initiation to first evidence of disease progression or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-progression data was calculated using Greenwood's formula.</description>
          <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.7" lower_limit="4.1" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Dose Limiting Toxicity</title>
        <description>Dose limiting toxicity by serious adverse events by CTCAE version 4.0</description>
        <time_frame>8 months.</time_frame>
        <population>This outcome was for phase 1 only</population>
        <group_list>
          <group group_id="O1">
            <title>Bavituximab:0.3 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
            <description>Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily&#xD;
bavituximab (0.3 mg/kg) and sorafenib: Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Bavituximab: 1.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
            <description>Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily&#xD;
bavituximab (1.0 mg/kg ) and sorafenib: Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O3">
            <title>Bavituximab: 3.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily</title>
            <description>Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily&#xD;
bavituximab (3.0 mg/kg) and sorafenib: Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Dose Limiting Toxicity</title>
          <description>Dose limiting toxicity by serious adverse events by CTCAE version 4.0</description>
          <population>This outcome was for phase 1 only</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety, as Measured by the Number of Patients With Adverse Event Related to the Treatment That Experienced Grade 3 or Greater.</title>
        <description>Safety was measured by the number of patients with at least one adverse event as assess by NCI Common Terminology criteria for adverse events (CTCAE)</description>
        <time_frame>Up to 3 months of patient enrollment (phase 1)</time_frame>
        <population>This outcome measure was only analyzed for phase 1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Safety, as Measured by the Number of Patients With Adverse Event Related to the Treatment That Experienced Grade 3 or Greater.</title>
          <description>Safety was measured by the number of patients with at least one adverse event as assess by NCI Common Terminology criteria for adverse events (CTCAE)</description>
          <population>This outcome measure was only analyzed for phase 1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Months of Overall Survival Calculated From Treatment Initiation to Death or Last Follow-up.</title>
        <description>Median months of overall survival was calculated from treatment initiation to death or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for median months of overall survival was calculated using Greenwood's formula.</description>
        <time_frame>Treatment initiation to death or last follow-up, an average 24 months</time_frame>
        <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Months of Overall Survival Calculated From Treatment Initiation to Death or Last Follow-up.</title>
          <description>Median months of overall survival was calculated from treatment initiation to death or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for median months of overall survival was calculated using Greenwood's formula.</description>
          <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.1" lower_limit="4.9" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.</title>
        <description>Median months of disease specific survival was calculated from treatment initiation to first evidence of death from advanced liver cancer or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-disease specific survival data was calculated using Greenwood's formula.</description>
        <time_frame>Treatment initiation to first evidence of death from advanced liver cancer or last follow-up, an average of 12 months</time_frame>
        <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.</title>
          <description>Median months of disease specific survival was calculated from treatment initiation to first evidence of death from advanced liver cancer or last follow-up by using the Kaplan-Meier method. The 95% confidence intervals (CIs) for time-to-disease specific survival data was calculated using Greenwood's formula.</description>
          <population>Cohort 1 and 2 were part of phase 1 study and at the phase 1 study this outcome was not collected. The 3 participants who received dose Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily were part of phase 1 and hence they were not part of phase 2 . Hence their data were not analyzed here.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="8.6" lower_limit="6.2" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and Other AEs were monitored up to 8 months (Phase 1) SAEs and Other AEs were monitored up to 2 years (Phase 2)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gerd</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>infusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>hiccoughs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>stomstitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand /foot syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Yopp, MD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-5870</phone>
      <email>adam.yopp@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

